NXN-188
- Generic Name
- NXN-188
- Drug Type
- Small Molecule
- Background
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
- Indication
Investigated for use/treatment in migraine and cluster headaches.
Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- NeurAxon Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT00959751
- Locations
- ๐บ๐ธ
Comprehensive Neuroscience, Inc., St. Petersburg, Florida, United States
๐บ๐ธElkind Headache Center, Mount Vernon, New York, United States
๐บ๐ธComprehensive NeuroScience, Inc. Atlanta, Atlanta, Georgia, United States
Study of NXN 188 for the Treatment of Migraine With Aura
- Conditions
- Migraine With Aura
- Interventions
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- NeurAxon Inc.
- Target Recruit Count
- 239
- Registration Number
- NCT00920686
- Locations
- ๐บ๐ธ
The Research Center of Southern California, LLC, Oceanside, California, United States
๐บ๐ธC. Philip O'Carrroll, MD, Inc., Newport Beach, California, United States
๐บ๐ธSan Francisco Headache Clinic, San Francisco, California, United States
Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura
- Conditions
- Migraine With Aura
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 40
- Registration Number
- NCT00877838
- Locations
- ๐ฉ๐ฐ
Danish Headache Center, Glostrup, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.